Company Encyclopedia
View More
name
Acumen Pharmaceuticals
ABOS.US
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug.
1.945 T
ABOS.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Acumen Pharmaceuticals Unveils Enhanced Brain Delivery Technology for Alzheimer’s Antibody in Phase 2 Trial

    Acumen Pharmaceuticals announced at the CTAD conference the development of enhanced brain delivery technology for Alzheimer's antibodies, using the transferrin receptor pathway. This aims to improve the efficacy-to-safety ratio of treatments like sabirnetug (ACU193). The company also shared recruitment strategies from the Phase 2 ALTITUDE-AD trial, highlighting effective participant enrollment methods. The findings were presented at the conference, with data available on Acumen's website.

    Reuters·
    US
    ABOS
    -6.06%
    Reuters·
    US
    ABOS
    -6.06%

    Bank of America Securities Remains a Buy on Acumen Pharmaceuticals (ABOS)

    Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Acumen Pharmaceuticals with a price target of $8.00. Zemansky is a 5-star analyst with an average return of 21.3% and a 60.64% success rate. The analyst consensus on Acumen Pharmaceuticals is a Strong Buy with an average price target of $6.50.

    Tip Ranks·
    US
    ABOS
    -6.06%
    Tip Ranks·
    US
    ABOS
    -6.06%

    Acumen Pharmaceuticals Doses First Participant in Phase 2 Extension Study of Sabirnetug for Early Alzheimer’s Disease

    Acumen Pharmaceuticals Inc. has dosed the first participant in the open-label extension phase of its Phase 2 ALTITUDE-AD clinical trial for early Alzheimer’s disease. Participants who completed the initial 18-month placebo-controlled portion will receive sabirnetug at 35 mg/kg intravenously every four weeks for an additional 52 weeks. The study will monitor clinical measures and safety, with topline results expected in late 2026.

    Reuters·
    US
    ABOS
    -6.06%
    Reuters·
    US
    ABOS
    -6.06%

    Acumen Pharmaceuticals (NASDAQ:ABOS) Upgraded by Wall Street Zen to "Hold" Rating

    Wall Street Zen upgraded Acumen Pharmaceuticals from a "strong sell" to a "hold" rating. Other analysts have mixed views, with some maintaining a sell rating and others a buy. The stock opened at $1.73, with a market cap of $104.79 million. Acumen focuses on Alzheimer's therapies and recently reported better-than-expected earnings. Institutional investors hold 71.01% of the stock. Despite a moderate buy rating, some analysts suggest better investment options.

    Market Beat·
    US
    ABOS
    -6.06%
    Market Beat·
    US
    ABOS
    -6.06%

    Citi Sticks to Its Buy Rating for Acumen Pharmaceuticals (ABOS)

    Citi analyst Geoff Meacham maintains a Buy rating for Acumen Pharmaceuticals with a $4.00 price target. Shares closed at $1.95. Meacham, a 4-star analyst, has a 5.7% average return and 56.39% success rate, focusing on Healthcare stocks. Acumen has a Strong Buy consensus with a $5.67 price target.

    Tip Ranks·
    US
    ABOS
    -6.06%
    Tip Ranks·
    US
    ABOS
    -6.06%
    © 2025 Longbridge｜Disclaimer